№ files_lp_4_process_3_071648
File format: docx
Character count: 5278
File size: 27 KB
Experimental protocols and analyses detailing the preparation, staining, imaging, and molecular assays of hematopoietic stem cells, marrow stromal cells, and leukemia cells in mice, serving as a supplement to primary research publications.
Year:
2010–2015
Institution:
University Hospitals Case Medical Center
Field:
Biomedical Research / Hematology
Document Type:
Research Methods Supplement
Techniques:
Immunohistochemistry, Flow Cytometry, Multi-photon Intravital Imaging, Chromatin Immunoprecipitation, Luciferase Reporter Assay, Western Blot, qRT-PCR
Model Organisms:
Mice (including leukemia models)
Authors:
Myers JT, Barkauskas DS, Huang AY, Wang W, Yu S, Zimmerman G, Wang Y, Yu VW, Huang D, Huang X, Shim J, Huang Y, Xin W, Qiao P, Yan M, Scadden DT, Stanley P, Lowe JB, Zhou L, Yao D
Target Cells:
Hematopoietic stem cells, marrow stromal cells, leukemia cells
Reagents and Antibodies:
Hes1, RBPJ, JAG1, ICN1, ICN2, GFP, Annexin V, CD41, CXCL12, GAPDH
Culture Conditions:
α-MEM medium, serum-free medium, supplements including mSCF and TPO
Imaging Equipment:
SP5/AOBS/2-photon microscope, Leica Microsystems, Imaris software
Analytical Methods:
qRT-PCR, fluorescence imaging, statistical analysis
References:
Myers JT et al., Stem Cells International 2013; Myers J et al., Transfusion 2010; Wang W et al., Stem Cells 2015; Yao D et al., Blood 2011
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Omaha, NE
Theme:
Hematopoietic Cellular Therapy
Document Type:
Standard Operating Procedure
Organization / Institution:
FACT Accreditation
Author:
FACT
Target Audience:
Medical Facilities, Accreditation Inspectors
Period of Validity:
N/A
Date of Approval:
December 14, 2021
Date of Changes:
N/A
Year:
2021
Region / City:
Not specified
Theme:
Hematology, Leukemia, Molecular Biology
Document Type:
Research Supplementary Figure
Author:
Not specified
Target Audience:
Researchers in the field of leukemia and hematopoiesis
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2023
Region / City:
United States
Topic:
Hematopoietic Cell Transplantation, Cellular Therapies, Research Databases
Document Type:
Consent Form
Organization / Institution:
CIBMTR (Center for International Blood and Marrow Transplant Research)
Author:
CIBMTR
Target Audience:
Patients and/or parents/legal guardians of recipients of hematopoietic cell transplants or cellular therapies
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2026
Region / City:
Barcelona, Spain
Theme:
Hematopoietic stem cell transplant, chronic graft-versus-host disease, patient-reported outcomes
Document Type:
Research article
Organization / Institution:
Hospital de la Santa Creu i Sant Pau, Institut d’Investigacio Contra la Leucemia Josep Carreras, Moffitt Cancer Center, St. Anna Children’s Hospital
Authors:
Anna Barata, Anita Lawitschka
Target Audience:
Medical professionals, researchers, clinicians, healthcare providers
Period of Effect:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2021
Region / City:
Not specified
Theme:
Hematology, Leukemia, Molecular Biology
Document Type:
Research Supplementary Figure
Author:
Not specified
Target Audience:
Researchers in the field of leukemia and hematopoiesis
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2000–2022
Study Type:
Clinical research
Patient Population:
ABL-class leukemia patients
Sample Type:
Bone marrow and blood DNA
Assay Methods:
RNA sequencing, targeted locus amplification (TLA), genomic capture high throughput sequencing (gc-HTS), Fusion Detection by Gene Enrichment (FUDGE), long-range PCR, Sanger sequencing
Quantitative Assay:
MRD Q-PCR based on genomic breakpoints and IG/TR targets
Institution:
Princess Máxima Centrum, Netherlands; USEQ sequencing facility, Utrecht, Netherlands; Macrogen Europe
Ethics:
Written informed consent obtained according to the Declaration of Helsinki
Data Tables:
Supplemental Digital Tables 1–3
Figures:
Supplemental Digital Figures 1–2
Reference Protocols:
EuroMRD guidelines
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified
Year:
Not specified
Disease:
Acute Myeloid Leukemia (AML)
Genetic Focus:
FLT3 mutations (TKD, ITD, ITD-TKD)
Treatment Groups:
FLT3 inhibitors (FLT3i) vs Conventional Chemotherapy (CT)
Endpoints:
Overall Survival (OS); Event-Free Survival (EFS); Time to Transplant
Study Period:
Before and after 2018 approval of FLT3 inhibitors
Statistical Methods:
Logistic regression; Propensity score weighting; Inverse probability weighting; Cox proportional hazard models; Mediation analysis; Sensitivity analysis
Confounders Considered:
Sex; Age; AML type; FLT3 mutation type; White-blood cell count; Platelet count; ELN risk classification; Ongoing comorbidities
Risk Classification System:
European LeukemiaNet (ELN)
Supplementary Material:
Table S1 (subgroup analyses with inverse probability weighting); Table S2 (baseline characteristic survival analyses)
Key Measures:
Hazard Ratios (HR); 95% Confidence Intervals (CI); p-values
Regulatory Milestone Referenced:
Clinical approval of FLT3 inhibitors in 2018
Name:
William D. Marrero-León, MD
Current Position:
Clinical Fellow, Leukemia Fellowship Program
Institution:
The University of Texas MD Anderson Cancer Center
Start Date:
July 2025
Specialty:
Hematology and Medical Oncology
Board Certification:
Internal Medicine; Hematology
Clinical Interests:
Targeted therapies; molecular markers in leukemia treatment
Medical School:
Iberoamerican University School of Medicine
Residency:
Internal Medicine, San Juan City Hospital
Previous Appointment:
Faculty Member, University District Hospital
Additional Training:
Fellowship in Hematology and Medical Oncology, San Juan City Hospital
Leadership Role:
Chief Fellow
Awards:
First Prize in Clinical Research (twice), Puerto Rico Hematology Oncology Convention
Research Focus:
Molecular and cytogenetic abnormalities in acute myeloid leukemia (AML) patients in Puerto Rico
Mentor:
Fernando Cabanillas
Publications:
Two peer-reviewed publications
Year:
2017
Region / City:
N/A
Topic:
Hematologic Toxicities, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Document Type:
Meta-analysis
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Healthcare Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
2/2018
Year:
2021
Region / city:
Not specified
Topic:
Mesenchymal cells in bone marrow of AML patients
Document type:
Research Supplementary Data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2013–2019
Cell Type:
THP-1 acute myeloid leukemia; Jurkat acute lymphoid leukemia
Treatment:
Apigenin (AP), Etoposide (ETP), Cyclophosphamide (CYCLO)
Assay Method:
Proteome ProfilerTM - Human Apoptosis Array
Measured Proteins:
BAD, BAX, BCL2, BCLX, CYT c, SMAC/DIBALO, HTRA2/OMI, TRAILR1/DR4, TNFR1/TNFRSF1A, FAS/D95, FADD, CASP-3
Exposure Time:
24 hours
Effect Type:
Synergistic increase or decrease in apoptosis-related protein expression
Reference Studies:
Mahbub et al., 2013; 2015; 2019
Data Format:
Supplementary Figures
Year:
2023
Region / City:
Cambridge, Massachusetts; Denver, Colorado; Philadelphia, Pennsylvania
Subject:
Pinometostat treatment, leukemia research, resistance mechanisms
Document Type:
Research Methods Supplement
Author(s):
Carly T. Campbell, Jessica N. Haladyna, David A. Drubin, Ty M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, Jesse J. Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle
Target Audience:
Researchers, biotechnologists, and medical professionals in oncology and pharmacology
Period of Validity:
2023
Approval Date:
2023
Modification Date:
N/A
Methodology:
Sanger sequencing, RNA-seq, ChIP-Seq, Quantitative PCR, Western Blot, Transporter Study
Context:
Detailed supplemental methods and experimental procedures for studying resistance mechanisms to Pinometostat in MLL rearranged leukemia cells, including sequencing, immunoprecipitation, and transporter studies.
Year:
2023
Region / city:
Pittsburgh, PA, U.S.A.
Topic:
Hematology, Oncology, Dermatology
Document type:
Case Report
Institution:
Allegheny General Hospital
Author:
Muhammad Ali Butt, Sameen Aamer, Anastasios Kapetanos
Target audience:
Healthcare professionals, researchers in hematology and oncology
Date of approval:
Not specified
Date of changes:
Not specified
Keywords:
Henoch-Schonlein Purpura, acute myeloid leukemia, cutaneous presentation of acute myeloid leukemia
Abstract:
This document reports an unusual case of Henoch-Schonlein Purpura (HSP) as the presenting symptom of Acute Myeloid Leukemia (AML).
Contextual description:
A case report of a patient who presented with a rash consistent with Henoch-Schonlein Purpura, later diagnosed with Acute Myeloid Leukemia.
Year:
2026
Region:
International
Subject:
Pediatric acute lymphoblastic leukemia
Document type:
Supplemental digital content
Institution:
Multiple international cooperative study groups
Authors:
Østergaard, A et al.
Study groups:
BFM, IC BFM, ANZCHOG, DCOG, NOPHO, UKALL, MB, GBTLI, JACLS, CoALL
Datasets:
A, B, C
Methodology:
MRD-guided protocols and survival analysis
Outcome measures:
Event-free survival, relapse rate, overall survival
Context:
Dataset tables and Kaplan-Meier survival curves evaluating prognostic significance of IKZF1 deletions in childhood acute lymphoblastic leukemia across multiple study protocols
Year:
2024
Location:
Harare, Zimbabwe
Study type:
Cross-sectional hospital study
Subject:
Pediatric acute leukemia
Sample size:
44 patients
Age range:
0–17 years
Sex distribution:
26 female, 18 male
Leukemia subtype:
AML 56.8%, ALL 43.2%
Genetic factors:
Down syndrome 13.6%, Neurofibromatosis 20.5%
Haematological abnormalities:
Anaemia 80%, Thrombocytopenia 78%, Low RBC count 70%, Leukocytosis 60%
Treatment follow-up:
Persistent cytopenias during chemotherapy
Institution:
Parirenyatwa Group of Hospitals
Data collection period:
January–September 2024
Clinical parameters:
Hemoglobin, platelet count, RBC and WBC counts, MRD levels where available
Analytical tools:
SPSS v26, descriptive statistics, chi-square and t-tests
Year:
2023
Region / City:
Not specified
Topic:
Leukemia Cutis, Chronic Myeloid Leukemia
Document Type:
Case Report
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2016
Region / City:
Fort Eustis, Virginia
Topic:
Military Awards and Decorations
Document Type:
Regulation
Organization:
U.S. Army Training and Doctrine Command (TRADOC)
Author:
Deputy Chief of Staff, G-3/5/7, G-34 (Protection Directorate)
Target Audience:
TRADOC Military Police Law and Order Detachments
Period of Validity:
Annual
Approval Date:
16 September 2016
Change Date:
16 September 2016
Note:
Year
Name:
Yiqin Du
Position Title:
Professor
Current Institution:
University of South Florida
Field of Expertise:
Ophthalmology; Stem Cell Biology
Education:
MD in Clinical Medicine; PhD in Ophthalmology
Research Areas:
Corneal regeneration; Trabecular meshwork regeneration; Glaucoma; Stem cell therapies
Clinical Background:
Ophthalmology; Cornea and glaucoma surgery
Employment History:
Xuzhou Third Hospital; University of Pittsburgh; University of South Florida
Grant Support:
NIH/NEI R01 grants
Funding Agencies:
National Institutes of Health; National Eye Institute
Research Period Covered:
1987–2029
Publications:
Peer-reviewed journal articles in ophthalmology and stem cell research
Authorship Role:
Principal Investigator; Co-Principal Investigator